Dyadic International, Inzymes announce planned 2026 commercialization

Dyadic Applied BioSolutions announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successful completion of final development activities under the companies’ collaboration agreement. Completion of these development activities represents a contractual milestone under the parties’ 2023 development and commercialization agreement focused on non-animal dairy enzymes produced using Dyadic’s proprietary microbial expression platforms.